Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-06
1999-07-13
Mach, D. Margaret M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514322, 546193, 546194, 546199, A61K 31415, A61K 31445, C07D 2458, C07D23522
Patent
active
059227370
ABSTRACT:
The present invention relates to novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl-amino)piperidin-1-yl)-2-(aryl)butyl )benzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
REFERENCES:
patent: 3282947 (1966-11-01), Grogan
patent: 3862173 (1975-01-01), Carr
patent: 4254129 (1981-03-01), Carr
patent: 4254130 (1981-03-01), Carr
patent: 4285958 (1981-08-01), Carr
patent: 4550116 (1985-10-01), Soto
patent: 4588722 (1986-05-01), Janssens
patent: 4598079 (1986-07-01), Beyerle
patent: 4666905 (1987-05-01), Downs
patent: 4835161 (1989-05-01), Janssens
patent: 4908372 (1990-03-01), Carr
patent: 4960776 (1990-10-01), Walsh
patent: 4988689 (1991-01-01), Janssens
patent: 5023256 (1991-06-01), Roberto
patent: 5166136 (1992-11-01), Ward
patent: 5182399 (1993-01-01), Kane
patent: 5212187 (1993-05-01), Alisch
patent: 5214040 (1993-05-01), Cuberes-Alatisent
patent: 5236921 (1993-08-01), Emonds-Alt
patent: 5272150 (1993-12-01), Janssens
patent: 5317020 (1994-05-01), Emonds-Alt
patent: 5322850 (1994-06-01), Orjales-Venero
patent: 5371093 (1994-12-01), Carr
patent: 5434158 (1995-07-01), Shah
Barnes, et al., TIPS 11:185-189 (May 1990).
Ichinose, et al., The Lancet 340:1248-1251 (Nov. 21, 1992).
Hagiwara, et al., "Studies on Neurokinin Antagonists 2.", Journal of Medicinal Chemistry, vol. 35, No. 17, 3184-3191, 1992.
Hagiwara, et al., Studies on Neurokinin Antagonists 1., J. Med. Chem, 35, 2015-2025, 1992.
Janssens, et al., J. Med. Chem. 28:1934-1943, (1985).
Janssens, et al., Drug Development Research 8:27-36, (1986).
Jannssens, et al., J. Med. Chem.,28(12):1925-1933, (1985).
Iemura, et al., Chem. Pharm. Bull., 37(4):967-972, (1989).
Janssens, et al., J. Med. Chem., 28(12):1943-1947, (1985).
Carr et al., The J. Organic Chem., 55(4):1399-1401, (1990).
Iemura, et al., Chem. Pharm. Bull., 37(4):962-966, (1989).
Maynard, Biorganic and Medicinal Chemistry Letters, vol. 3 (4), 753-756, 1993.
Wahlgren, J. Heterocyclic Chem., 26, 541-543, 1989.
Iemura, Chem. Pharm. Bull., 37(4), 967-972, 1989.
Iemura, J. Heterocyclic Che., 24, 31-37, 1987.
Daijiro Hagiwara et. al., "Design of a Novel Dipeptide Substance P Antagonist FK888 and Its Pharmacological Profile", Fujisawa Pharmacetucial Co., Ltd.
Iemura, et al., J. Med. Chem., 29(7):1178-1183, (1986).
Hagiwara, et al., Studies on Neurokinin Antagonists 3., J. Med. Chem, 36, 2266-2278, 1993.
Emonds-Alt, et al., Life Sciences, 56(1):27-32, (1995).
Melloni, et al., Eur. J. Med. Chem., 26, 207-21 (1991).
Devillier, P. et al. Eur. J. Pharmacol., 1985 (Oct. 29, 117(1), pp. 89-96.
Ward, et al., J. Med. Chem. 38, 4985-4992 (1995).
Armour, et al., Bkiorganic & Med. Chem. Letters, 6(9), 1015-1020 (1996).
Bratton Larry Don
Dalton Christopher Robin
Kane John Michael
Kudlacz Elizabeth Mary
Maynard George Daniel
Hoechst Marion Roussel Inc.
Kurys Barbara E.
M. Mach D. Margaret
Stemerick Dave
LandOfFree
Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2276001